Photo of Daniel P. Petrylak from medicine.yale.edu
Sep 15, 2024, 16:36
Promising Results for Sacituzumab Govitecan in Cisplatin-Ineligible Metastatic Urothelial Cancer
Eda Eylemer Mocan, Medical oncologist at Ankara university, shared a recent article by Daniel P. Petrylak on X:
“TROPHY-U-01 Cohort 2
SG in Metastatic Urothelial Cancer
- Cisplatin-Ineligible
- Progressing after ICI
- Med f/u 9.3 m, ORR 32%, DOR 5.6 m
- Grade ≥3 AE 87% of pts
- Neutropenia 34%
- Anemia 24%
- Fatigue 18%
- Diarrhea 16%
Authors: Daniel P. Petrylak, MD, Scott T. Tagawa, MD, Rohit K. Jain, MD, Manojkumar Bupathi, MD, Arjun Balar, MD,Arash Rezazadeh Kalebasty, MD, Saby George, MD and Petros Grivas, MD, PhD
Source: Eda Eylmer Mocan/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Feb 21, 2025, 15:06
Feb 21, 2025, 14:27
Feb 21, 2025, 14:13
Feb 21, 2025, 13:29